Results 191 to 200 of about 370,229 (352)

Polypharmacy in Adults With Systemic Lupus Erythematosus. [PDF]

Arthritis Care Res (Hoboken)
Yang J, Growdon ME, Fitzpatrick J, Dunlop-Thomas C, Hoge C, Covinsky KE, Bowling CB, Lim SS, Yazdany J, Plantinga LC.   +9 more
europepmc   +1 more source

Chemokines in systemic lupus erythematosus involving the central nervous system [PDF]

, 2007
Tsuyoshi Kasama
openalex   +1 more source

Reactive Oxygen Species–Induced Modifications of Fibrin Clots as a Link Between Immune Responses and Atherothrombosis in Systemic Lupus Erythematosus

Arthritis &Rheumatology, EarlyView.
Objective Cardiovascular events are major determinants of morbidity and mortality in systemic lupus erythematosus (SLE), particularly in patients with renal involvement. Although oxidative stress has been implicated in driving vascular and renal damage in SLE, the specific mechanisms remain unclear.
Matteo Becatti, Giacomo Emmi, Alessandra Bettiol, Amanda Mannucci, Flavia Rita Argento, Eleonora Fini, Serena Borghi, Francesca Nencini, Maria Nicastro, Irene Mattioli, Elena Silvestri, Augusto Vaglio, Domenico Prisco, Claudia Fiorillo   +13 more
wiley   +1 more source

An Overview of the Pathogenesis of Cutaneous Lupus Erythematosus. [PDF]

J Clin Med
Verdelli A, Barletta E, Mariotti EB, Landini S, Magnatta A, Ruffo di Calabria V, Corrà A, Quintarelli L, Bonanni I, Sanna L, Corti V, Caproni M.   +11 more
europepmc   +1 more source

Correction: Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from japan and south korea [PDF]

openalex   +1 more source

Cytokine pathways driving diverse tissue pathologies in rheumatoid arthritis

Arthritis &Rheumatology, Accepted Article.
Rheumatoid arthritis is a complex systemic disorder characterised primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease e.g. of the lung with potentially devastating clinical consequences.
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

Challenges in the diagnosis of systemic lupus erythematosus. [PDF]

Clin Med (Lond)
Scopes J, Md Yusof MY.
europepmc   +1 more source

Systemic Lupus Erythematosus [PDF]

Postgraduate Medical Journal, 1958
T F, McCARTHY, D P, MISRA
openaire   +2 more sources

A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus

Arthritis &Rheumatology, EarlyView.
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen, Duanping Liao, Judith A. James, Joel M. Guthridge, Cristina Arriens, Diane Kamen, Mariko Ishimori, Daniel J. Wallace, Christopher Striebich, Sonali Narain, Benjamin F. Chong, Fan He, Eric W. Schaefer, Vernon M. Chinchilli, David R. Karp   +14 more
wiley   +1 more source

Cardiac Involvement in Systemic Lupus Erythematosus. [PDF]

Rev Cardiovasc Med
Vyas V, Vyas V, Sharma A, Kumar PA.
europepmc   +1 more source